The immunosuppression role of alpha-fetoprotein in human hepatocellular carcinoma

Discovery Medicine

Volumn 21, Issue 118, 2016, Pages

  Meng, Wenbo ^a   Bai, Bing ^a   Bai, Zhongtian ^a   Li, Yan ^b   Yue, Ping ^b   Li, Xun ^a   Qiao, Liang ^c  

^a LANZHOU UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CYTOKINE; INTERLEUKIN 12; TUMOR MARKER; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; DENDRITIC CELL; GENE EXPRESSION; HUMAN; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; MACROPHAGE; PHAGOCYTOSIS; TUMOR GROWTH; TUMOR INVASION; ADOPTIVE IMMUNOTHERAPY; BLOOD; CARCINOMA, HEPATOCELLULAR; CELLULAR IMMUNITY; EARLY CANCER DIAGNOSIS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER; LIVER NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES; PROGNOSIS; RISK FACTOR;

ALPHA-FETOPROTEINS; APOPTOSIS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; EARLY DETECTION OF CANCER; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; LIVER; LIVER NEOPLASMS; MOLECULAR TARGETED THERAPY; PROGNOSIS; RISK FACTORS;

EID: 85007333792     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Abu El Makarem M. An overview of biomarkers for the diagnosis of hepatocellular carcinoma. Hepat Mon 12(10 HCC):e6122, 2012.
2. Alisa A, Ives A, Pathan AA, Navarrete CV, Williams R, Bertoletti A, Behboudi S. Analysis of CD4+ T-Cell responses to a novel alpha-fetoprotein-derived epitope in hepatocellular carcinoma patients. Clin Cancer Res 11(18):6686-6694, 2005.
3. Anurathapan U, Leen AM, Brenner MK, Vera JF. Engineered T cells for cancer treatment. Cytotherapy 16:713-733, 2014.
4. Atemezem A, Mbemba E, Marfaing R, Vaysse J, Pontet M, Saffar L, Charnaux N, Gattegno L. Human alpha-fetoprotein binds to primary macrophages. Biochem Biophys Res Commun 296(3):507-514, 2002.
5. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene 25(27):3866-3884, 2006.
6. Ball D, Rose E, Alpert E. Alpha-fetoprotein levels in normal adults. Am J Med Sci 303(3):157-159 1992.
7. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 28(5):753-770, 2014.
8. Breous E, Thimme R. Potential of immunotherapy for hepatocellular carcinoma. J Hepatol 54(4):830-834, 2011.
9. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 11(1):191-207, x-xi, 2007.
10. Butterfield LH. Recent advances in immunotherapy for hepatocellular cancer. Swiss Med Wkly 137(5-6):83-90, 2007.
11. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med 12:86, 2014.
12. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res 59(13):3134-3142, 1999.
13. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. J Immunol 166(8):5300-5308, 2001.
14. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12(9):2817-2825, 2006.
15. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res 9(16 Pt 1):5902-5908, 2003.
16. Butterfield LH, Ribas A, Potter DM, Economou JS. Spontaneous and vaccine induced AFP-specific T cell phenotypes in subjects with AFP-positive hepatocellular cancer. Cancer Immunol Immunother 56(12):1931-1943, 2007.
17. Butterfield LH, Economou JS, Gamblin TC, Geller DA. Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med 12:86, 2014.
18. Bériot M, Tchimbou AF, Barbato O, Beckers JF, de Sousa NM. Identification of pregnancy-associated glycoproteins and alpha-fetoprotein in fallow deer (Dama dama) placenta. Acta Vet Scand 56:4, 2014.
19. Cooke NE, David EV. Serum vitamin D-binding protein is a third member of the albumin and alpha fetoprotein gene family. J Clin Invest 76(6):2420-2424, 1985.
20. Crainie M, Semeluk A, Lee KC, Wegmann T. Regulation of constitutive and lymphokine-induced Ia expression by murine alpha-fetoprotein. Cell Immunol 118(1):41-52, 1989.
21. Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta 395(1-2):19-26, 2008.
22. Dudich I, Tokhtamysheva N, Semenkova L, Dudich E, Hellman J, Korpela T. Isolation and structural and functional characterization of two stable peptic fragments of human alpha-fetoprotein. Biochemistry 38(32):10406-10414, 1999.
23. Evdokimova VN, Liu Y, Potter DM, Butterfield LH. AFP-specific CD4+ helper T-cell responses in healthy donors and HCC patients. J Immunother 30(4):425-437, 2007.
24. Farrell GC, Chan HL, Yuen MF, Amarapurkar DN, Chutaputti A, Fan JG, Hou JL, Han KH, Kao JH, Lim SG, Mohamed R, Sollano J, Ueno Y. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J Gastroen Hepatol 25(4):657-663, 2010.
25. Gao H, Li K, Tu H, Pan X, Jiang H, Shi B, Kong J, Wang H, Yang S, Gu J, Li Z. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 15;20(24):6418-6428, 2014.
26. Gillespie JR, Uversky VN. Structure and function of alpha-fetoprotein: a biophysical overview. Biochim Biophys Acta 1480(1-2):41-56, 2000.
27. González-Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, Schmidt-Wolf IG, Sauerbruch T, Caselmann WH. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int 26(3):369-379, 2006.
28. Hanke P, Rabe C, Serwe M, Böhm S, Pagenstecher C, Sauerbruch T, Caselmann WH. Cirrhotic patients with or without hepatocellular carcinoma harbour AFP-specific T-lymphocytes that can be activated in vitro by human alpha-fetoprotein. Scand J Gastroenterol 37(8):949-955, 2002.
29. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y, Lin C, Pan Z, Yu Y, Jiang M, Zhou W, Cao X. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2, 3-dioxygenase production in hepatocellular carcinoma. Hepatology 59(2):567-579, 2014.
30. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature 358(6383):209-215, 1992.
31. Hong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, Butterfield LH, Mivechi NF, Munn DH, Bartlett DL, He Y. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology 59(4):1448-1458, 2014.
32. Irony-Tur-Sinai M, Grigoriadis N, Tsiantoulas D, Touloumi O, Abramsky O, Brenner T. Immunomodulation of EAE by alpha-fetoprotein involves elevation of immune cell apoptosis markers and the transcription factor FoxP3. J Neurol Sci 279(1-2):80-87, 2009.
33. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 5(1):145-159, 2001.
34. Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas. Anticancer Res 25(6A):3771-3776, 2005.
35. Keel BA, Harms RL, Leal JA, Cho S. Characterization of human alpha fetoprotein charge microheterogeneity during fetal development. Mol Reprod Dev 27(4):281-287, 1990.
36. Krebs K, Böttinger N, Huang LR, Chmielewski M, Arzberger S, Gasteiger G, Jäger C, Schmitt E, Bohne F, Aichler M, Uckert W, Abken H, Heikenwalder M, Knolle P, Protzer U. T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology 145(2):456-465, 2013.
37. Lan YH, Li YG, Liang ZW, Chen M, Peng ML, Tang L, Hu HD, Ren H. A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma. Cancer Immunol Immunother 56(7):1009-1016, 2007.
38. Lichtenegger FS, Krupka C, Köhnke T, Subklewe M. Immunotherapy for Acute Myeloid Leukemia. Semin Hematol 52(3):207-214, 2015.
39. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta 313(1-2):15-19, 2001.
40. Liu Y, Butterfield LH, Fu X, Song Z, Zhang X, Lu C, Ding G, Wu M. Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo. Int J Oncol 39(1):245-253, 2011.
41. Li YL, Ma HB, Guo JX, Shi JB, Xu J, Liu AX, Yang LH, Li BA, Mao YL. The studies on early warning of Lens culinaris-reactive alpha-Fetoprotein (AFP-L3) detecting in primary hepatocellular carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 22(5):336-338, 2008.
42. Mato A, Porter DL. A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood 126(4):478-485, 2015.
43. Matsuura E, Kang Y, Kitakawa H, Ogata A, Kotani T, Ohtaki S, Nishi S. Modulation of T cell function by alpha-fetoprotein: An in vivo study on porcine thyroid peroxidase-induced experimental autoimmune thyroiditis in transgenic mice producing human alpha-fetoprotein. Tumour Biol 20(3):162-171, 1999.
44. Morita Y, Hiramatsu N, Fujita T, Amano H, Katsumata E, Arai K, Iwasaki T, Todo T, Hara A. Characterization of alpha-fetoprotein levels in three dolphin species: development of sensitive immunoassays for analysis of the pregnancy-associated variations. J Reprod Dev 59(4):368-377, 2013.
45. Mukhtar O, Zaheer F, Malik MF, Khan JS, Ijaz T. Socio-demographic study of hepatitis c patients visiting tertiary care hospital. J Ayub Med Coll Abbottabad 27(3):650-652, 2015.
46. Nicholas NS, Panayi GS. Immunosuppressive properties of pregnancy serum on the mixed lymphocyte reaction. Br J Obstet Gynaecol 93(12):1251-1255, 1986.
47. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology 1(1):48-55, 2012.
48. Pardee AD, Shi J, Butterfield LH. Tumor-derived a-fetoprotein impairs the differentiation and T cell stimulatory activity of human dendritic cells. J Immunol 193(11):5723-5732, 2014.
49. Pang XH, Chen MS, Jia WH, Zhou XX. Inhibitory effects of human AFP-derived peptide-pulsed dendritic cells on mouse hepatocellular carcinoma. Ai Zheng 27(12):1233-1238, 2008.
50. Pedroza-Gonzalez A, Zhou G, Vargas-Mendez E, Boor PP, Mancham S, Verhoef C, Polak WG, Grünhagen D, Pan Q, Janssen H, Garcia-Romo GS, Biermann K, Tjwa ET, IJzermans JN, Kwekkeboom J, Sprengers D. Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncoimmunology 4(6):e1008355, 2015.
51. Pucci P, Siciliano R, Malorni A, Marino G, Tecce MF, Ceccarini C, Terrana B. Human alpha-fetoprotein primary structure: a mass spectrometric study. Biochemistry 30(20):5061-5066, 1991.
52. Redman BG, Chang AE, Whitfield J, Esper P, Jiang G, Braun T, Roessler B, Mulé JJ. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother 31(6):591-598, 2008.
53. Rich N, Singal AG. Hepatocellular carcinoma tumour markers: Current role and expectations. Best Pract Res Clin Gastroenterol 28(5):843-853, 2014.
54. Ritter M, Ali MY, Grimm CF, Weth R, Mohr L, Bocher WO, Endrulat K, Wedemeyer H, Blum HE, Geissler M. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. J Hepatol 41(6):999-1007, 2004.
55. Sen G, Rai R, Manas DM. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 90(8):1022, 2003.
56. Shimizu K, Katoh H, Yamashita F, Tanaka M, Tanikawa K, Taketa K, Satomura S, Matsuura S. Comparison of carbohydrate structures of serum alpha-fetoprotein by sequential glycosidase digestion and lectin affinity electrophoresis. Clin Chim Acta 254(1):23-40, 1996.
57. Sun Z, Zhu Y, Xia J, Sawakami T, Kokudo N, Zhang N. Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. Biosci Trends, epub ahead of print, Nov. 2, 2015.
58. Tanwandee T, Setthasin S, Charatcharoenwitthaya P, Chainuvati S, Leelakusolvong S, Pausawasdi N, Srikureja W, Pongprasobchai S, Manatsathit S, Kachintorn U, Ekpo P, Senawong S. Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a Thai referral population. J Med Assoc Thai 92 (Suppl 2):S49-S56, 2009.
59. Um SH, Mulhall C, Alisa A, Ives AR, Karani J, Williams R, Bertoletti A, Behboudi S. Alpha-fetoprotein impairs APC function and induces their apoptosis. J Immunol 173(3):1772-1778, 2004.
60. Weber M. Cancer-killing CAR therapies gain speed. Cancer Discov 5(1):7, 2015.
61. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180(5):3122-3131, 2008.
62. Yang JY, Cao DY, Xue Y, Yu ZC, Liu WC. Improvement of dendritic-based vaccine efficacy against hepatitis B virus-related hepatocellular carcinoma by two tumor-associated antigen gene-infected dendritic cells. Hum Immunol 71(3):255-262, 2010.
63. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 10(9):1070-1076, 2003.
64. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 19(1):91-99, 2005.